As Chief Financial Officer, Sandra oversees financial strategy and discipline, including financial planning & analysis (FP&A), accounting, and the company’s strategic investment across the various business units with a focus on supporting the company’s rapid growth. Throughout her 20 years of experience in both public and private capital markets, she has successfully raised equity and debt financing and led several high-profile M&As and strategic partnerships. All of these skills are well suited to the next phase of Crossover’s journey.
Most recently, Sandra served as CFO at San Francisco-based Vida Health, where she spearheaded three oversubscribed financing rounds resulting in $200 million in funding to provide a variety of digital health services to Fortune 500 companies and health plans. Previously she was CFO both at online genetic counseling firm Genome Medical, Inc., and at Glooko, Inc., a diabetes-focused global SaaS company. Earlier in her career, Ms. Cavanah co-founded genetic engineering company Open Monoclonal Technology, Inc., and led its sale to Ligand Pharmaceuticals, Inc.
Ms. Cavanah earned an MBA from Harvard Business School and a BS in Business Administration from the University of California, Berkeley.